BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, testing, and delivering transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Founded in 2015 and headquartered in Palo Alto, California, the company's mission is to bridge the gap between scientific advancements and effective therapies, addressing significant unmet medical needs, particularly in rare diseases.

BridgeBio focuses on a diverse pipeline spanning Mendelian disorders, precision oncology, and gene therapy. Key products and investigational therapies include Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM), and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency (MoCD) Type A, both of which are approved. The company's late-stage pipeline features BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), for which an NDA was submitted in March 2026, encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1) with an NDA planned for the first half of 2026, and infigratinib for achondroplasia and hypochondroplasia. The company operates on a hub-and-spoke model, allowing autonomous teams to focus on specific conditions while leveraging central clinical, regulatory, and commercial capabilities.

Led by co-founder and CEO Neil Kumar, Ph.D., BridgeBio has demonstrated strong market positioning, with Attruby sales exceeding projections in 2025, reaching $362 million. The company reported full-year 2025 revenues of $502.1 million and is scheduled to release its first quarter 2026 financial results on May 7, 2026. In 2024, BridgeBio strategically spun out its KRAS-focused cancer portfolio into BridgeBio Oncology Therapeutics and early-stage assets into GondolaBio, further solidifying its focus on a robust and diversified pipeline.